Literature DB >> 31780559

Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design.

Pierce J Ogden1,2,3, Eric D Kelsic4,2,5, Sam Sinai1,2,5,6, George M Church4,2,3,5.   

Abstract

Adeno-associated virus (AAV) capsids can deliver transformative gene therapies, but our understanding of AAV biology remains incomplete. We generated the complete first-order AAV2 capsid fitness landscape, characterizing all single-codon substitutions, insertions, and deletions across multiple functions relevant for in vivo delivery. We discovered a frameshifted gene in the VP1 region that expresses a membrane-associated accessory protein that limits AAV production through competitive exclusion. Mutant biodistribution revealed the importance of both surface-exposed and buried residues, with a few phenotypic profiles characterizing most variants. Finally, we algorithmically designed and experimentally verified a diverse in vivo targeted capsid library with viability far exceeding random mutagenesis approaches. These results demonstrate the power of systematic mutagenesis for deciphering complex genomes and the potential of empirical machine-guided protein engineering.
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31780559      PMCID: PMC7197022          DOI: 10.1126/science.aaw2900

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  14 in total

1.  ADENOVIRUS-ASSOCIATED DEFECTIVE VIRUS PARTICLES.

Authors:  R W ATCHISON; B C CASTO; W M HAMMON
Journal:  Science       Date:  1965-08-13       Impact factor: 47.728

2.  Structure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20.

Authors:  Dustin M McCraw; Jason K O'Donnell; Kenneth A Taylor; Scott M Stagg; Michael S Chapman
Journal:  Virology       Date:  2012-06-09       Impact factor: 3.616

Review 3.  E Pluribus Unum: 50 Years of Research, Millions of Viruses, and One Goal--Tailored Acceleration of AAV Evolution.

Authors:  Dirk Grimm; Sergei Zolotukhin
Journal:  Mol Ther       Date:  2015-09-21       Impact factor: 11.454

4.  Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.

Authors:  Stephen Russell; Jean Bennett; Jennifer A Wellman; Daniel C Chung; Zi-Fan Yu; Amy Tillman; Janet Wittes; Julie Pappas; Okan Elci; Sarah McCague; Dominique Cross; Kathleen A Marshall; Jean Walshire; Taylor L Kehoe; Hannah Reichert; Maria Davis; Leslie Raffini; Lindsey A George; F Parker Hudson; Laura Dingfield; Xiaosong Zhu; Julia A Haller; Elliott H Sohn; Vinit B Mahajan; Wanda Pfeifer; Michelle Weckmann; Chris Johnson; Dina Gewaily; Arlene Drack; Edwin Stone; Katie Wachtel; Francesca Simonelli; Bart P Leroy; J Fraser Wright; Katherine A High; Albert M Maguire
Journal:  Lancet       Date:  2017-07-14       Impact factor: 79.321

5.  A viral assembly factor promotes AAV2 capsid formation in the nucleolus.

Authors:  Florian Sonntag; Kristin Schmidt; Jürgen A Kleinschmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

Review 6.  Adeno-associated virus vector as a platform for gene therapy delivery.

Authors:  Dan Wang; Phillip W L Tai; Guangping Gao
Journal:  Nat Rev Drug Discov       Date:  2019-05       Impact factor: 84.694

7.  High capsid-genome correlation facilitates creation of AAV libraries for directed evolution.

Authors:  Mathieu Nonnenmacher; Harm van Bakel; Roger J Hajjar; Thomas Weber
Journal:  Mol Ther       Date:  2015-01-14       Impact factor: 11.454

8.  Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy.

Authors:  Jerry R Mendell; Samiah Al-Zaidy; Richard Shell; W Dave Arnold; Louise R Rodino-Klapac; Thomas W Prior; Linda Lowes; Lindsay Alfano; Katherine Berry; Kathleen Church; John T Kissel; Sukumar Nagendran; James L'Italien; Douglas M Sproule; Courtney Wells; Jessica A Cardenas; Marjet D Heitzer; Allan Kaspar; Sarah Corcoran; Lyndsey Braun; Shibi Likhite; Carlos Miranda; Kathrin Meyer; K D Foust; Arthur H M Burghes; Brian K Kaspar
Journal:  N Engl J Med       Date:  2017-11-02       Impact factor: 91.245

9.  Subcellular compartmentalization of adeno-associated virus type 2 assembly.

Authors:  A Wistuba; A Kern; S Weger; D Grimm; J A Kleinschmidt
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

10.  The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication.

Authors:  Maohua Cao; Hong You; Paul L Hermonat
Journal:  PLoS One       Date:  2014-08-15       Impact factor: 3.240

View more
  72 in total

1.  Adeno-Associated Virus Genome Interactions Important for Vector Production and Transduction.

Authors:  Anna C Maurer; Matthew D Weitzman
Journal:  Hum Gene Ther       Date:  2020-05       Impact factor: 5.695

Review 2.  Regulators of Viral Frameshifting: More Than RNA Influences Translation Events.

Authors:  Wesley D Penn; Haley R Harrington; Jonathan P Schlebach; Suchetana Mukhopadhyay
Journal:  Annu Rev Virol       Date:  2020-06-29       Impact factor: 10.431

3.  Effects of Altering HSPG Binding and Capsid Hydrophilicity on Retinal Transduction by AAV.

Authors:  Sean M Crosson; Antonette Bennett; Diego Fajardo; James J Peterson; Hangning Zhang; Wei Li; Matthew T Leahy; Colin K Jennings; Ryan F Boyd; Sanford L Boye; Mavis Agbandge-McKenna; Shannon E Boye
Journal:  J Virol       Date:  2021-03-03       Impact factor: 5.103

Review 4.  AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer.

Authors:  Helena Costa Verdera; Klaudia Kuranda; Federico Mingozzi
Journal:  Mol Ther       Date:  2020-01-10       Impact factor: 11.454

Review 5.  Modulating gene regulation to treat genetic disorders.

Authors:  Navneet Matharu; Nadav Ahituv
Journal:  Nat Rev Drug Discov       Date:  2020-10-05       Impact factor: 84.694

Review 6.  Best of most possible worlds: Hybrid gene therapy vectors based on parvoviruses and heterologous viruses.

Authors:  Julia Fakhiri; Dirk Grimm
Journal:  Mol Ther       Date:  2021-04-05       Impact factor: 11.454

7.  Frustration and Direct-Coupling Analyses to Predict Formation and Function of Adeno-Associated Virus.

Authors:  Nicole N Thadani; Qin Zhou; Kiara Reyes Gamas; Susan Butler; Carlos Bueno; Nicholas P Schafer; Faruck Morcos; Peter G Wolynes; Junghae Suh
Journal:  Biophys J       Date:  2020-12-25       Impact factor: 4.033

Review 8.  Viral tools for neuroscience.

Authors:  Alexander R Nectow; Eric J Nestler
Journal:  Nat Rev Neurosci       Date:  2020-10-27       Impact factor: 34.870

9.  Capsid Proteins Are Necessary for Replication of a Parvovirus.

Authors:  Thomas Labadie; Deborah Garcia; Doriane Mutuel; Mylène Ogliastro; Guillaume Cambray
Journal:  J Virol       Date:  2021-08-10       Impact factor: 5.103

Review 10.  Overcoming innate immune barriers that impede AAV gene therapy vectors.

Authors:  Manish Muhuri; Yukiko Maeda; Hong Ma; Sanjay Ram; Katherine A Fitzgerald; Phillip Wl Tai; Guangping Gao
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.